Key result
Sacubitril/Valsartan therapy for 6 months significantly improved left ventricular ejection fraction from 29% to 37% and reduced indexed end-systolic and end-diastolic volumes in patients with HFrEF.
Why the study?
Effects of sacubitril/valsartan on left ventricular mechanics and ventricular-arterial coupling in patients with HFrEF are not completely understood.
Does sacubitril/valsartan improve cardiac and vascular remodeling in patients with HFrEF?
Observational (n=50)
No
Does sacubitril/valsartan improve cardiac and vascular remodeling in patients with HFrEF?
Absolute Event Rate: 37% vs 29%
p-value: p=<0.001
Sacubitril/valsartan therapy in HFrEF patients leads to significant cardiac and vascular reverse remodeling, improving myocardial contractility, hemodynamic force distribution, and ventricular-arterial coupling at 6 months.
S/V therapy was associated with improved LV remodeling and VAC in HFrEF; leaves open whether these changes translate to better outcomes in prospective trials.
Background Effects of Sacubitril/Valsartan (S/V) on left ventricular (LV) mechanics and ventricular-arterial coupling in patients with heart failure with reduced ejection fraction (HFrEF) are not completely understood. The aim of this study was to evaluate both cardiac and vascular remodeling in a group of HFrEF patients undergoing S/V therapy. Methods Fifty HFrEF patients eligible to start a therapy with S/V were enrolled. Echocardiographic evaluation was performed at baseline and after 6 months of follow-up (FU). Beside standard evaluation, including global longitudinal strain (GLS), estimated hemodynamic forces (HDFs) and non-invasive pressure-volume curves (PV loop) were assessed using dedicated softwares. HDFs were evaluated over the entire cardiac cycle, in systole and diastole, both in apex to base (A-B) and latero-septal (L-S) directions. The distribution of LV HDFs was evaluated by L-S over A-B HDFs ratio (L-S/A-B HDFs ratio). Parameters derived from estimated PV loop curves were left ventricular end-systolic elastance (Ees), arterial elastance (Ea), and ventricular-arterial coupling (VAC). Results At 6 months of FU indexed left ventricular end-diastolic and end-systolic volumes decreased (EDVi: 101 ± 28 mL vs. 86 ± 30 mL, p < 0.001; ESVi: 72 ± 23 mL vs. 55 ± 24 mL, p < 0.001), ejection fraction and GLS significantly improved (EF: 29 ± 6% vs. 37 ± 7%, p < 0.001; GLS: −9 ± 3% vs. −13 ± 4%, p < 0.001). A reduction of Ea (2.11 ± 0.91 mmHg/mL vs. 1.72 ± 0.44 mmHg/mL, p = 0.008) and an improvement of Ees (1.01 ± 0.37 mmHg/mL vs. 1.35 ± 0.6 mmHg/mL, p < 0.001) and VAC (2.3 ± 1.1 vs. 1.5 ± 0.7, p < 0.001) were observed. Re-alignment of HDFs occurred, with a reduction of diastolic L-S/A-B HDFs ratio [23 (20–35)% vs. 20 (11–28) %, p < 0.001]. Conclusion S/V therapy leads to a complex phenomenon of reverse remodeling involving increased myocardial contractility, HDFs distribution improvement, and afterload reduction.
No takes yet. Share an insight, caveat, or question.
Monosilio et al. (2022) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=50). Sacubitril/Valsartan vs. Baseline (before starting therapy) was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.001). Sacubitril/Valsartan therapy for 6 months significantly improved left ventricular ejection fraction from 29% to 37% and reduced indexed end-systolic and end-diastolic volumes in patients with HFrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: